Aligos Therapeutics, Inc. announced that it has completed enrollment in the ALG-055009 Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis (MASH) with topline safety and efficacy data anticipated in early fourth quarter 2024. The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study. HERALD (NCT06342947) is a randomized, double-blind, placebo-controlled trial that has enrolled approximately 100 subjects with presumed MASH and stage 1-3 liver fibrosis (F1-F3).

Subjects were randomized to receive one of four doses (0.3, 0.5, 0.7, 0.9 mg) of ALG-055009 or placebo (20 subjects/arm) given orally once daily for 12 weeks. The primary endpoint is relative change in liver fat content by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) at week 12. Safety, pharmacokinetics (PK) and other non-invasive biomarkers/tests previously shown to be impacted by treatment with thyroid hormone receptor beta (THR-ss) inhibitors will also be evaluated.